BridgeBio Pharma (NASDAQ:BBIO) Director Hannah Valantine Sells 2,196 Shares of Stock

BridgeBio Pharma, Inc. (NASDAQ:BBIO) Director Hannah Valantine sold 2,196 shares of the business’s stock in a transaction dated Tuesday, June 23rd. The shares were sold at an average price of $68.57, for a total value of $150,579.72. Following the completion of the transaction, the director owned 9,259 shares in the company, valued at $634,889.63. The trade was a 19.17% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Hannah Valantine also recently made the following trade(s):

• On Monday, June 22nd, Hannah Valantine sold 2,808 shares of BridgeBio Pharma stock. The stock was sold at an average price of $68.00, for a total value of $190,944.00.

BridgeBio Pharma Trading Up 0.9%

NASDAQ:BBIO opened at $69.26 on Thursday. The stock has a 50-day moving average price of $69.20 and a 200 day moving average price of $71.86. The stock has a market capitalization of $13.56 billion, a P/E ratio of -18.52 and a beta of 0.97. BridgeBio Pharma, Inc. has a 12-month low of $41.80 and a 12-month high of $84.94.

BridgeBio Pharma (NASDAQ:BBIO) last posted its quarterly earnings results on Thursday, May 7th. The company reported ($0.84) EPS for the quarter, missing analysts’ consensus estimates of ($0.70) by ($0.14). The company had revenue of $194.51 million during the quarter, compared to the consensus estimate of $178.07 million. During the same quarter in the previous year, the company posted ($0.88) earnings per share. The company’s quarterly revenue was up 66.8% compared to the same quarter last year. On average, research analysts predict that BridgeBio Pharma, Inc. will post -2.29 earnings per share for the current fiscal year.

Institutional Trading of BridgeBio Pharma

Several hedge funds have recently modified their holdings of the company. Jones Financial Companies Lllp purchased a new position in shares of BridgeBio Pharma in the first quarter valued at $35,000. First Trust Advisors LP raised its stake in BridgeBio Pharma by 200.4% during the second quarter. First Trust Advisors LP now owns 263,693 shares of the company’s stock valued at $11,386,000 after purchasing an additional 175,918 shares in the last quarter. Baird Financial Group Inc. lifted its position in BridgeBio Pharma by 1.8% during the second quarter. Baird Financial Group Inc. now owns 42,057 shares of the company’s stock valued at $1,816,000 after purchasing an additional 731 shares during the last quarter. DZ BANK AG Deutsche Zentral Genossenschafts Bank Frankfurt am Main bought a new position in BridgeBio Pharma during the second quarter valued at $1,650,000. Finally, MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. grew its stake in shares of BridgeBio Pharma by 2.4% in the 2nd quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 95,326 shares of the company’s stock worth $4,132,000 after buying an additional 2,206 shares in the last quarter. 99.85% of the stock is owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

Several equities analysts have recently commented on BBIO shares. Raymond James Financial downgraded shares of BridgeBio Pharma from an “outperform” rating to a “market perform” rating in a report on Tuesday, May 26th. Leerink Partners reaffirmed an “outperform” rating and set a $98.00 target price on shares of BridgeBio Pharma in a research note on Thursday, March 12th. Mizuho reduced their price target on shares of BridgeBio Pharma from $106.00 to $96.00 and set an “outperform” rating on the stock in a report on Tuesday, June 16th. William Blair initiated coverage on shares of BridgeBio Pharma in a research note on Tuesday, March 10th. They issued an “outperform” rating on the stock. Finally, Morgan Stanley increased their price objective on shares of BridgeBio Pharma from $94.00 to $98.00 and gave the company an “overweight” rating in a report on Thursday, May 28th. Twenty-one analysts have rated the stock with a Buy rating, two have given a Hold rating and one has given a Sell rating to the stock. According to MarketBeat, BridgeBio Pharma presently has a consensus rating of “Moderate Buy” and a consensus target price of $92.90.

BridgeBio Pharma Company Profile

BridgeBio Pharma, Inc is a clinical-stage biopharmaceutical company headquartered in Palo Alto, California. Founded in 2015 by Neil Kumar, the company is dedicated to discovering, developing and delivering transformative medicines for patients with genetic diseases and cancers. BridgeBio operates an integrated model that spans target identification, preclinical research, clinical development and commercialization, aiming to streamline the process from bench to bedside.

BridgeBio’s pipeline comprises multiple therapeutic modalities, including small molecules, biologics and genetic therapies.